News

Vor Bio has signed an exclusive license agreement to develop and market Remegen’s telitacicept — a B-cell-targeting candidate for the treatment of myasthenia gravis (MG) and other autoimmune diseases driven by self-reactive antibodies — outside of China, Hong Kong, Macau, and Taiwan. Telitacicept has been approved…

Telitacicept, a B-cell-targeting therapy for myasthenia gravis (MG), has been granted orphan drug status in the European Union, according to its developer Remegen. Orphan drug designation, or ODD, is awarded to medications that treat conditions affecting fewer than 5 in 10,000 people in the EU. The designation’s…

A six-week program that combines inspiratory muscle training (IMT) and aerobic exercise may improve respiratory function in adults with myasthenia gravis (MG), a study in Taiwan shows. Those who followed the training showed strengthened respiratory muscles, improved lung function, reduced breathlessness, and enhanced physical fitness over those who received…

Women who have surgery to remove their thymus gland to treat myasthenia gravis (MG) tend to have experienced symptoms earlier in life than men, but waited longer to receive a diagnosis, a study reports. However, after the surgery, called a thymectomy, female patients have higher rates of complete…

The U.S. Food and Drug Administration (FDA) has cleared the launch of a Phase 2 clinical trial testing IM-101, ImmunAbs’ investigational therapy for myasthenia gravis (MG). The multicenter, placebo-controlled trial is expected to enroll up to 90 people with MG who will receive IM-101 or a placebo once monthly.

The first patient has joined a Phase 3 clinical trial assessing the safety and efficacy of Descartes-08, an investigational cell therapy for myasthenia gravis (MG) being developed by Cartesian Therapeutics. Called AURORA (NCT06799247), the trial is expected to enroll 100 adults with generalized MG (gMG), a more…

Organizations are holding events and activities in June in recognition of Myasthenia Gravis Awareness Month, an annual observance that aims to raise awareness of myasthenia gravis (MG), an autoimmune disease that affects 90,000-100,000 people in the U.S. alone. “Throughout June, Myasthenia Gravis News is recognizing awareness month with a…

Using tears to test for self-reactive antibodies to help diagnose ocular myasthenia gravis (OMG) is more accurate than using blood samples, according to a study that found nearly all patients who tested negative for these antibodies in the blood had a positive result in tears. “Tear-based testing offers a…

Remegen’s telitacicept has been approved in China as an add-on treatment for adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR) — that’s approximately 80% of all gMG patients, per the company. The decision, by the country’s National Medical Products Administration…

A rare form of myasthenia gravis that manifests in childhood and adolescence called juvenile myasthenia gravis (JMG) affects roughly 30 out of every 1 million children in the U.S., and may be more common than previously thought, a study estimates. The study also found that JMG is more common…